Ritonavir , ≥98% , 155213-67-5
Synonym(s):
;Ritonavir
CAS NO.：155213-67-5
Empirical Formula: C37H48N6O5S2
Molecular Weight: 720.94
MDL number: MFCD04115732
EINECS: 605-001-5
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB74.40 | In Stock |
|
| 50MG | RMB151.20 | In Stock |
|
| 250MG | RMB399.20 | In Stock |
|
| 500mg | RMB503.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 120-122°C |
| Boiling point: | 947.0±65.0 °C(Predicted) |
| Density | 1.239±0.06 g/cm3(Predicted) |
| Flash point: | 2℃ |
| storage temp. | room temp |
| solubility | DMSO: soluble10mg/mL (clear solution, warmed) |
| pka | 11.47±0.46(Predicted) |
| form | powder |
| color | white to beige |
| Water Solubility | 5mg/L(ms) |
| Merck | 14,8238 |
| BCS Class | 2,4 |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months. |
| InChIKey | NCDNCNXCDXHOMX-XGKFQTDJSA-N |
Description and Uses
Ritonavir (brand name: Norvir) was launched in Germany, the UK and US for treatment of advanced HIV in combination with antiretroviral nucleoside analogs in a record 72 days by the FDA. It is an inhibitor of HIV aspartic protease which is critical in the processing of a propeptide into the gag, gag-pol gene products and the protease itself. This inhibition results in the release of non-infectous immature virus particles. It is greater than 500-fold more selective for viral aspartic protease than the human version, has good oral bioavailability and may increase the bioavailability of other protease inhibitors. Ritonavir was able to increase the CD4 and CD8 lymphocyte count as well as reduce viral RNA. It is more potent than saqunavir and comparible in potency to zidovudine and lamivudine.
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients. Ritonivir is an HIV protease inhibitor (EC50 = 25 nM) that also inhibits CYP3A4, the primary cytochrome P450 isoform that metabolizes protease inhibitors. Through CYP3A4 inhibition, low doses of ritonivir can reduce the metabolism of concomitantly administered protease inhibitiors, enhancing their bioavailability and efficacy.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302+H312+H332 |
| Precautionary statements | P261-P264-P280-P301+P312-P302+P352+P312-P304+P340+P312 |
| Hazard Codes | Xi,Xn |
| Risk Statements | 36/38-20/21/22-41 |
| Safety Statements | 26-37/39-36/37-39 |
| RIDADR | UN 1648 3 / PGII |
| WGK Germany | 3 |
| RTECS | XA5310000 |
| HS Code | 29341000 |
